Somatic activating mutations, such as exon 21 L858R point mutation and exon19 deletion, in the epidermal growth factor receptor (EGFR) are observed in ~15% of Caucasian patients and up to 50% of East-Asian patients with NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.